Qureight secures £500k in seed funding from CMS Ventures to launch its next platform version
CMS Ventures has backed the Cambridge clinical analytics start-up in its latest funding round.
Cambridge based data company Qureight develops a platform that structures image and clinical metadata to track complex diseases.
Qureight has secured £500k in seed funding from CMS Ventures to launch the second iteration of its platform. The capital will also support team expansion and the analysis of upcoming clinical trial data for various respiratory illnesses.
Founded in 2018, the start-up works with partners in healthcare and pharmaceuticals to convert raw patient data into structured models for diagnosis and treatment. The investment marks the first output of a collaboration between CMS, AstraZeneca, and the Cambridge Judge Business School.
From the founder
"This investment will allow us to grow our team and capitalise on recent partnerships in industry to analyse upcoming clinical trial data in a number of respiratory diseases. Crucially, it will allow us to launch the next iteration of our platform to deeper integrate with large data sets. We are really excited that CMS Ventures has decided to join us on the journey as we scale the company. By unlocking the data from an individual patient journey, we will be able to help many others with the same diseases."
Muhunthan Thillai
CEO at Qureight
Investor perspective
"The CMS investment in Qureight is a success on multiple fronts: it is a win for the Cambridge ecosystem, for the brilliant team at Qureight, and it marks the first fruit of the collaboration launched earlier this year between CMS, AstraZeneca, and CJBS.This partnership aims to bridge a gap in the funding in the UK for biotech and life sciences early stage ventures; building on the strategic partnership that AstraZeneca and CJBS have developed since 2015 and that has seen over 80 AZ employees engage, mentor, and grow local biotech and life sciences startups.This investment illustrates how valuable the hard work put in jointly by CJBS and AstraZeneca is in supporting new and ambitious founders from a scientific background, such as Dr Thillai and Dr Ruggiero, by helping them navigate and structure organisational, commercial, and financial issues; and by acting as a catalyst to turn their ideas into reality."
Christoph Loch
Dean of the Cambridge Judge Business School, CJBS
Use of funds
- 01Grow the team
- 02Continue product development
Investors
Categories
About the company
Qureight
Qureight builds a data platform to track complex diseases and improve clinical trials.